INOMIXO Inc. specializes in advanced omics technologies, particularly focusing on mass spectrometry for proteomics, peptidomics, metabolomics, and spatial omics. Their services include comprehensive analysis for both academic and biopharmaceutical research, enabling detailed characterization of proteins, peptides, and metabolites. The company employs both top-down and bottom-up proteomics methodologies, allowing for the direct analysis of intact proteins as well as the digestion of proteins into smaller peptides for enhanced sensitivity and throughput. This dual approach facilitates the identification of post-translational modifications and provides insights into protein interactions, which are crucial for understanding drug mechanisms and optimizing therapeutic strategies.

Additionally, INOMIXO offers custom manufacturing services for mRNA drug products, supporting the entire process from RNA design to IND filing. Their capabilities include scalable production of high-quality mRNA and linearized plasmid DNA, essential for in vitro transcription. The company emphasizes rigorous quality control testing to ensure the purity and efficacy of their mRNA products, which are vital for the development of mRNA-based therapies. By integrating these advanced technologies and services, INOMIXO aims to accelerate research and development in the fields of biomedical research and biopharmaceutical analysis.

Hong Kong

INOMIXO is an innovative company dedicated to providing multi-omics solutions in the field of life sciences. By integrating AI big data with advanced mass spectrometry multi-omics technology, along with our team of experienced R&D expertise, INOMIXO has developed two primary business segments, academic omics services and biopharmaceutical CRO services, creating a business landscape that provides solid, professional, and cutting-edge omics solutions for developing life sciences.

INOMIXO Inc.

Company Details